Recent studies have revealed that dysregulated Rab
small GTPase-mediated vesicle trafficking pathways are associated with
cancer progression. However, whether any of the Rabs plays a suppressor role in
cancer stemness is least explored. Rab37 has been postulated as a
tumor suppressive
small GTPase for trafficking anti-
tumor cargos. Here, we report a previously uncharacterized mechanism by which Rab37 mediates exocytosis of
secreted frizzled-related protein-1 (SFRP1), an extracellular antagonist of Wnt, to suppress Wnt signaling and
cancer stemness in vitro and in vivo. Reconstitution experiments indicate that SFRP1 secretion is crucial for Rab37-mediated
cancer stemness suppression and treatment with SRPP1
recombinant protein reduces xenograft
tumor initiation ability. Clinical results confirm that concordantly low Rab37, low SFRP1, and high Oct4 stemness
protein expression profile can be used as a
biomarker to predict poor prognosis in
lung cancer patients. Our findings reveal that Rab37-mediated SFRP1 secretion suppresses
cancer stemness, and dysregulated Rab37-SFRP1 pathway confers
cancer stemness via the activation of Wnt signaling. Rab37-SFRP1-Wnt axis could be a potential therapeutic target for attenuating
lung cancer stemness.